Pages that link to "Q35623852"
The following pages link to Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines (Q35623852):
Displaying 50 items.
- Cell reprogramming and neuronal differentiation applied to neurodegenerative diseases: Focus on Parkinson's disease (Q28080770) (← links)
- Induced Pluripotent Stem Cells: Global Research Trends (Q33914515) (← links)
- Creation of a library of induced pluripotent stem cells from Parkinsonian patients. (Q33917317) (← links)
- cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications (Q34045021) (← links)
- Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations (Q36020884) (← links)
- Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration (Q36079187) (← links)
- Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease (Q36372732) (← links)
- Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications. (Q37034262) (← links)
- Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation (Q37337917) (← links)
- Alterations in the E3 ligases Parkin and CHIP result in unique metabolic signaling defects and mitochondrial quality control issues (Q38603276) (← links)
- Induced pluripotent stem cells and Parkinson's disease: modelling and treatment (Q38691269) (← links)
- Induced pluripotent stem cell-based modeling of neurodegenerative diseases: a focus on autophagy. (Q38737027) (← links)
- Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects (Q38834545) (← links)
- Induced pluripotent stem cell technology: a decade of progress (Q39040578) (← links)
- Understanding Parkinson's Disease through the Use of Cell Reprogramming (Q39085008) (← links)
- The metabolic programming of stem cells (Q39185375) (← links)
- Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein? (Q41664833) (← links)
- Inappropriate trafficking of damaged mitochondria in Parkinson's disease (Q42318745) (← links)
- From the Cover: Manganese and Rotenone-Induced Oxidative Stress Signatures Differ in iPSC-Derived Human Dopamine Neurons (Q46298572) (← links)
- iPS cells in the study of PD molecular pathogenesis (Q46579323) (← links)
- Biological Implications of Differential Expression of Mitochondrial-Shaping Proteins in Parkinson's Disease. (Q47265377) (← links)
- The Role of ADHD Associated Genes in Neurodevelopment. (Q51730963) (← links)
- Modeling Neuropsychiatric and Neurodegenerative Diseases With Induced Pluripotent Stem Cells. (Q52431644) (← links)
- Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers. (Q52620145) (← links)
- Comparative analysis of Parkinson's disease-associated genes reveals altered survival and bioenergetics of parkin-deficient dopamine neurons in mice. (Q53071097) (← links)
- B119-iPSC (Q54752308) (← links)
- I3-iPSC (Q54897085) (← links)
- ND29369 (Q54929216) (← links)
- ND29543 (Q54929243) (← links)
- ND30171 (Q54929329) (← links)
- ND31618 (Q54929498) (← links)
- ND34791 (Q54929809) (← links)
- P1-iPSC (Q54937209) (← links)
- S110-iPSC (Q54951802) (← links)
- Y9-iPSC (Q54995196) (← links)
- Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes (Q57026122) (← links)
- T-type Calcium Channels Determine the Vulnerability of Dopaminergic Neurons to Mitochondrial Stress in Familial Parkinson Disease (Q57818216) (← links)
- Cross-species models of attention-deficit/hyperactivity disorder and autism spectrum disorder: lessons from CNTNAP2, ADGRL3, and PARK2 (Q58106959) (← links)
- Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells (Q58726898) (← links)
- Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models (Q58762401) (← links)
- Patient-Derived Induced Pluripotent Stem Cells and Organoids for Modeling Alpha Synuclein Propagation in Parkinson's Disease (Q59335760) (← links)
- Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease (Q63246542) (← links)
- One Step Into the Future: New iPSC Tools to Advance Research in Parkinson’s Disease and Neurological Disorders (Q64223489) (← links)
- The PARK10 gene USP24 is a negative regulator of autophagy and ULK1 protein stability (Q64769009) (← links)
- Induced pluripotent stem cell-based modeling of mutant LRRK2-associated Parkinson's disease (Q64785219) (← links)
- Parkinson's disease: what the model systems have taught us so far (Q64864829) (← links)
- Parkin New Cargos: a New ROS Independent Role for Parkin in Regulating Cell Division (Q89008606) (← links)
- Stem cells technology: a powerful tool behind new brain treatments (Q89146080) (← links)
- Modeling Cell-Cell Interactions in Parkinson's Disease Using Human Stem Cell-Based Models (Q89493904) (← links)
- Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson's disease (Q90237254) (← links)